Literature DB >> 2515927

Pathogenic potentials of bacterial proteases.

H Maeda1, A Molla.   

Abstract

Six separate molecular mechanisms for pathogenesis attributed to bacterial proteases are described. (I). Enhancements of vascular permeability and edema formation which result from the activation of kinin generating cascade such as Hageman factor by the proteases. (II). Degradation of defense oriented proteins including IgG and IgA as well as destruction of structural matrices such as fibronectin, proteoglycan and collagen. (III). Inactivation of complement system and generated chemotactic factor from C3 and C5. (IV). Degradation of regulatory plasma protease inhibitors (serpins) including alpha 1-protease inhibitor, alpha 2-macroglobulin (alpha 2M), C1-esterase inhibitor, alpha 2-antiplasmin and antithrombin-III. (V). The protease forms a transitory stable enzyme/inhibitor(alpha 2M) complex. It binds to and internalizes into the cells which possess alpha 2M-receptor such as fibroblasts via the alpha 2M-receptor, and the protease activity is regenerated in cells, and subsequently intracellular integrity is destroyed resulting in cell killing. (VI). The serratial 56 kDa (56K) protease is found to potential viral yield 100 fold more when influenza virus infected mice were subjected to administrations of this protease intranasally. This results in rapid and much elevated lethality.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2515927     DOI: 10.1016/0009-8981(89)90226-x

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  13 in total

1.  Molecular and functional characterization of a ToxR-regulated lipoprotein from a clinical isolate of Aeromonas hydrophila.

Authors:  Lakshmi Pillai; Jian Sha; Tatiana E Erova; Amin A Fadl; Bijay K Khajanchi; Ashok K Chopra
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  A 24-kDa cloned zinc metalloprotease from Actinobacillus pleuropneumoniae is common to all serotypes and cleaves actin in vitro.

Authors:  C García-Cuéllar; C Montañez; V Tenorio; J Reyes-Esparza; M J Durán; E Negrete; A Guerrero; M de la Garza
Journal:  Can J Vet Res       Date:  2000-04       Impact factor: 1.310

3.  Serratia marcescens serralysin induces inflammatory responses through protease-activated receptor 2.

Authors:  Yutaka Kida; Hiroyoshi Inoue; Takashi Shimizu; Koichi Kuwano
Journal:  Infect Immun       Date:  2006-10-16       Impact factor: 3.441

4.  Inactivation of chemotactic activity of C5a by the serratial 56-kilodalton protease.

Authors:  T Oda; Y Kojima; T Akaike; S Ijiri; A Molla; H Maeda
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

5.  Involvement of bradykinin generation in intravascular dissemination of Vibrio vulnificus and prevention of invasion by a bradykinin antagonist.

Authors:  K Maruo; T Akaike; T Ono; H Maeda
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

6.  Molecular and biochemical characterization of a protective 40-kilodalton antigen from Corynebacterium pseudotuberculosis.

Authors:  M J Wilson; M R Brandon; J Walker
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

7.  Purification and properties of the elastase from Aspergillus fumigatus.

Authors:  M Frosco; T Chase; J D Macmillan
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

8.  Serratia infections in patients with neutropenia.

Authors:  F Hartmann; T Gheorghiu; H Leupold; F Baer; V Diehl
Journal:  Klin Wochenschr       Date:  1991-08-01

9.  Virulence of a Porphyromonas gingivalis W83 mutant defective in the prtH gene.

Authors:  H M Fletcher; H A Schenkein; R M Morgan; K A Bailey; C R Berry; F L Macrina
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

10.  Phosphinic peptide analogues as potent inhibitors of Corynebacterium rathayii bacterial collagenase.

Authors:  A Yiotakis; A Lecoq; A Nicolaou; J Labadie; V Dive
Journal:  Biochem J       Date:  1994-10-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.